INCY vs INSM
Incyte vs Insmed Incorporated — AI-powered side-by-side comparison
VS
INSM
Insmed Incorporated
56
Watch
| Metric | INCY | INSM |
|---|
| AI Score |
72
|
56
|
| Price |
$121.08
|
$132.61
|
| P/E Ratio |
14.89×
|
-32.26×
|
| ROE |
24.9%
|
-172.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
83.3%
|
| Debt / Equity |
0.01×
|
0.05×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
78.9
|
| Beta |
0.769
|
0.793
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus INSM.
INCY leads by 16 points.
INCY scores 72/100 (Buy) versus INSM at 56/100 (Watch).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
INSM Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 185.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 50.2x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 185.8% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price-to-book of 50.2x prices in significant intangible value — Value
- ROE of only -111.3% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical